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Statement of findings
The present study was designed to analyze the level of B-cell clonal diversity in patients with
rheumatoid arthritis by using HCDR3 (third complementarity determining region of the
rearranged heavy chain variable region gene) length as a marker. A modified immunoglobulin
VH gene fingerprinting method using either genomic DNA or complementary (c)DNA derived
from B cells of the peripheral blood, synovial fluid, and tissues of several rheumatoid arthritis
patients was employed. These assays permitted the detection and distinction of numerically
expanded B-cell clones from activated but not numerically expanded B-cell clones. The
present data suggest that B-cell clonal expansion is a common and characteristic feature of
rheumatoid arthritis and that it occurs with increasing frequency from the blood to the synovial
compartments, resulting in a narrowing of the clonal repertoire at the synovial level. These
clonal expansions can involve resting, apparently memory B cells, as well as activated B cells.
Furthermore, some of these individual expansions can persist over extended periods of time.
These findings support the hypothesis that a chronic ongoing (auto)immune reaction is
operative in rheumatoid arthritis and that this reaction, at least at the B-cell level, may be
unique to each individual joint. A determination of the targets of these autoimmune reactions
may provide valuable clues to help understand the immunopathogenesis of this disease.
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Introduction
Rheumatoid arthritis is a chronic debilitating autoimmune
disease of unknown etiology. Although the disease is char-
acterized by synovitis of the joints, tendon sheaths, and
bursae, manifestations that do not involve the synovium are
not infrequent [1]. These articular and systemic manifesta-
tions appear to be mediated by immunologic processes [2].
The hallmarks of the synovial abnormalities in rheumatoid
arthritis are synovial lining cell proliferation, neoangiogene-
sis, and inflammatory cell infiltration involving the myeloid,
macrophage, and lymphoid lineages [1,2]. There has been
considerable controversy regarding the relative importance
of the types of cells and their products involved in the
inflammatory processes of rheumatoid arthritis [3]. Never-
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theless, it seems likely that all of these cell types participate
to some degree in disease pathogenesis.
Evidence in support of T-cell involvement in rheumatoid
arthritis involves the description of restricted subsets of T
cells in the blood and synovial tissue that either express or
lack certain surface membrane proteins or that express a
limited set of antigen receptors. For example, clonal amplifi-
cations of CD8+ CD57+ T cells are frequently found in the
T-cell repertoire of rheumatoid arthritis patients [4]. Further-
more, expanded clones of CD4+ CD28- T cells exist in the
blood and synovial compartments of such patients [5] and
these T cells appear to be autoreactive [6]. Finally, the T-
cell receptors for antigen expressed by these and other T-
cell subsets frequently display a bias in favor of receptors
utilizing certain Vβ genes [5,7–12].
In contrast to the extensive studies of the clonal distribu-
tion of T cells in rheumatoid arthritis, much less is known
about the level of B-cell diversity in this disease. Previous
studies, however, are consistent with the interpretation
that the B-cell repertoire is also restricted. For example,
flow cytometric analyses of circulating B cells [13] sug-
gested that oligoclonality exists, and cell culture experi-
ments [14–17] demonstrated that synovial tissue explants
spontaneously secrete immunoglobulins of restricted het-
erogeneity as defined by immunoglobulin (Ig)G subclass,
isoelectric focusing, and idiotype expression. More recent
molecular analyses of the immunoglobulin genes
expressed by B cells in the synovial tissue of rheumatoid
arthritis patients support these notions [18–22].
These findings are important because they suggest that,
at the B- and T-cell levels, an ongoing immune reaction is
occurring that is directed at restricted sets of (auto)anti-
gens. The present study was designed to analyze further
the level of clonal diversity in rheumatoid arthritis B cells
by using the length of the third complementarity determin-
ing region (CDR3) of the rearranged heavy (H) chain vari-
able region (V) gene as a marker (herein referred to as
HCDR3). A modification of the immunoglobulin VH gene
fingerprinting method [23] that has been used to analyze
the diversity of B cells and T cells in several clinical set-
tings [4,24–26] was used to address this issue. The
present data suggest that B-cell clonal expansion is a
common and characteristic feature of rheumatoid arthritis,
that it involves both resting and activated cells, and that it
can persist over extended periods of time. These findings
support the idea that a chronic (auto)immune reaction is
operative in rheumatoid arthritis.
Materials and methods
Patients and patient samples
Heparinized venous blood, synovial fluid, and synovial
tissue were obtained from patients who fulfilled the Ameri-
can College of Rheumatology criteria for the diagnosis of
rheumatoid arthritis [27]. Synovial tissue removed at the
time of either joint replacement or therapeutic synovec-
tomy was digested with collagenase, DNAse, and
hyaluronidase to obtain single-cell suspensions. Mononu-
clear cells (MNCs) were isolated from cell suspensions
from blood, synovial fluid, and synovial tissue by density
gradient centrifugation (Ficoll-Paque; Pharmacia LKB
Biotechnology, Piscataway, NJ, USA).
Isolation of DNA and RNA, and preparation of
complementary DNA
Genomic DNA was isolated from MNCs using the Pure-
gene DNA Isolation Kit (Gentra Systems, Mineapolis, MN,
USA) and total RNA was isolated using Ultraspec RNA
(Biotech Laboratories, Houston, TX, USA). Both of these
reagents were used according to the manufacturer’s
instructions. One microgram of RNA was reverse tran-
scribed to complementary (c)DNA using 200 U Moloney
murine leukemia virua (M-MLV) reverse transcriptase
(GIBCO BRL Life Technologies, Grand Island, NY, USA),
1 U RNAse inhibitor (5 Prime 3 Prime, Boulder, CO, USA)
and 20 pmol oligo dT primer in a total volume of 20 µl.
These ingredients were incubated at 42°C for 1 h, heated
to 65°C for 10 min to stop the reactions, and then diluted
to a final volume of 100 µl.
Polymerase chain reaction conditions for immunoglobulin
VH gene fingerprinting assay
The original immunoglobulin VH gene fingerprinting assay
[23] was modified into two stages, starting with either
genomic DNA or cDNA as templates (Fig. 1). The
sequences of the primers used in these reactions were
published previously [28].
Stage I
Genomic DNA (100 ng) was amplified using a sense VH
family-specific framework region (FR)1 primer in conjunc-
tion with an antisense JH consensus primer. These reac-
tions were carried out in 50 µl using 5 pmol of each primer,
and were cycled with a 9600 GeneAmp System (Perkin
Elmer, Emeryville, CA, USA) as follows: denaturation at
94°C for 40 s; annealing at 65°C for 45 s; and extension
at 72°C for 40 s. After 35 cycles, extension was continued
at 72°C for an additional 10 min.
cDNA (2 µl) was amplified using a sense VH family-specific
FR1 primer in conjunction with the appropriate antisense
CH primer. The reactions were carried out in 50 µl using 5
pmol of each primer and cycled as follows: denaturation at
94°C for 45s; annealing at 65°C for 45s; and extension at
72°C for 45s. After 35 cycles, extension was continued at
72°C for an additional 10min.
Stage II
Polymerase chain reaction (PCR) products (2µl) generated
from either genomic DNA or cDNA were amplified using
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5pmol of nested sense VH family-specific FR3 primer and
radiolabeled antisense nested JH consensus primer that had
been end-labeled with γ32-P (New England Nuclear, Beverly,
MA, USA) using T4 polynucleotide kinase (Promega,
Madison, WI, USA). The reactions were carried out in 25µl
and cycled as follows: denaturation at 94°C for 30s; anneal-
ing at 52°C for 45s; and extension at 72°C for 30s. After 15
cycles, extension was continued at 72°C for an additional
10min. The radiolabeled PCR products that reflected the
HCDR3 lengths of various B-cell clones in the cell suspen-
sion were electrophoresed through a 6% denaturing acry-
lamide sequencing gel for approximately 1.5h. The gel was
then dried and exposed to film overnight.
DNA cloning and sequencing
DNA sequences were determined by reamplifying the
original genomic DNA using the appropriate family-spe-
cific VH leader and JH consensus primers under the follow-
ing PCR conditions: denaturation at 94°C for 45 s;
annealing at 62°C for 30 s; and extension at 72°C for 45 s.
After 35 cycles, extension was continued at 72°C for an
additional 10 min. PCR products were then cloned into TA
vector (Invitrogen, San Diego, CA, USA), processed using
Wizard minipreps (Promega), and sequenced using M13
forward and reverse primers, a DNA Sequencing Kit
(Perkin Elmer) and an automated sequenator (Applied
Biosystems, Foster City, CA, USA).
Figure 1
Schematic representation of the two-stage VH fingerprinting assay
using either genomic DNA or complementary (c)DNA as templates. In
stage I for the genomic DNA-based assay, genomic DNA was
amplified using a sense VH family-specific FR1 primer in conjunction
with an antisense JH consensus primer. For the cDNA-based assay,
cDNA was amplified using a sense VH family-specific FR1 primer in
conjunction with the appropriate antisense CH primer. In stage II,
polymerase chain reaction (PCR) products generated from either
genomic DNA or cDNA were amplified using a nested sense VH family-
specific FR3 primer and a radiolabeled antisense nested JH consensus
primer that had been end-labeled with γ32-P. The radiolabeled PCR
products were electrophoresed through a 6% denaturing acrylamide
sequencing gel, and then exposed to photographic film overnight. See
text (Materials and methods) for further details. *Areas of coding end
processing at the D–JH and VH–DJH junctions. The VH fingerprinting
results displayed were derived with the cDNA-based assay.
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Results and discussion
Identification of B-cell clonal expansions using a modified
immunoglobulin VH gene fingerprinting assay
During normal B cell development, the processes of
gene segment recombination and coding end process-
ing yield nucleotide HCDR3 lengths that are characteris-
tic and virtually invariant for an individual B-cell clone.
Therefore, these lengths can be used as signatures to
identify members of a B cell clone. The immunoglobulin
VH gene fingerprinting approach [23] takes advantage of
the wide range of HCDR3 lengths that can occur in
human B cells (approximately 5–35 amino acids) to
provide an estimate of clonal diversity in polyclonal popu-
lations. When polyclonal B lymphocytes from adults are
analyzed using this assay, they display a Gaussian
HCDR3 length distribution around a mean of approxi-
mately 15 amino acids. The presence of an individual
dominant length that differs from this Gaussian distribu-
tion can be used as an indication of a specific B-cell
clonal expansion.
Figure 1 illustrates schematically the two-stage
immunoglobulin VH gene fingerprinting approach that
we utilized. Note that when cDNA prepared from normal
peripheral blood B cells is used as a template for these
VH family-specific and CH-specific assays, ladders of
HCDR3 lengths that differ by three nucleotides are
identified. These individual HCDR3 lengths are signa-
tures of the various individual B-cell clones contained
within the polyclonal population. The intensities of the
bands in virtually all of the ladders illustrated in Figure 1
are relatively uniformly distributed around the mean. This
indicates that there are no dominant HCDR3 lengths
that skew the Gaussian distribution, and therefore that
there are no significant clonal expansions among the B
cells that express most of these VH–CH combinations.
Similar results are obtained using the genomic DNA-
based assay, although these results cannot be inter-
preted in a CH-specific manner (data not shown).
In the VH6–IgG combination (Fig. 1), however, a non-
Gaussian distribution is noted, even in this normal individ-
ual. This could be a reflection of the numbers of VH genes
present in the VH family being analyzed (it is more likely to
see a non-Gaussian distribution in families with small
numbers of individual genes) or of the state of activation of
a specific clone (because activated B cells contain much
higher levels of V gene messenger RNA than resting B
cells). We believe that in the instance illustrated in
Figure 1 the latter possibility is more likely, because the
small VH2 and VH5 families (only two gene members per
family) do not exhibit the same degree of oligoclonality as
that observed with the only somewhat smaller VH6 family
(one gene member).
Distinction between clonal expansion and clonal activation
using the modified immunoglobulin VH gene fingerprinting
assay
Because B-cell activation and differentiation result in dra-
matic increases in immunoglobulin V gene messenger
RNA, these fingerprinting assays cannot readily distinguish
between clonal expansion and activation when cDNA is
used as a starting template. Because DNA levels are not
appreciably altered by cellular activation, however, the use
of genomic DNA as well as cDNA from the same sample of
B cells helps to distinguish these two processes.
Thus, in the setting of specific B-cell clonal expansion
without concomitant cellular activation, the DNA-based
fingerprinting assay will indicate a dominant HCDR3
length, whereas the cDNA-based assay may not (data not
shown). Conversely, in the setting of specific B-cell clonal
activation without concomitant clonal expansion, the
cDNA-based assay will indicate a dominant HCDR3
length, whereas the DNA-based assay may not. Finally, in
the setting of specific B-cell clonal activation with con-
comitant clonal expansion, both the cDNA- and the DNA-
based assays will indicate a dominant HCDR3 length.
These distinctions were very reproducible in the following
studies. There were no situations in which evidence for
cellular activation (either selective or accompanied by
clonal expansion) was present in one set of analyses and
not in a subsequent set using the same starting materials.
B cells in the blood, synovial fluid, and synovial tissue of
rheumatoid arthritis patients exhibit clonal expansions of
activated and resting B cells
We analyzed the peripheral blood, synovial fluid, and syn-
ovial tissue B cells of rheumatoid arthritis patients (n = 20,
10, and 5, respectively) using the genomic DNA- and
cDNA-based fingerprinting assays to develop an under-
standing of the diversity of the B cells in these compart-
ments. Figures 2 and 3 are illustrations of representative
patients for whom concomitant blood and synovial fluid or
blood and synovial tissue samples were available. In order
to simplify the Figures, only the results for two large VH
families (VH1 and VH3) and two small VH families (VH5 and
VH6) are provided, although assays for each VH family and
each major CH family (µ, γ, and α) were performed and
revealed similar findings.
The genomic DNA-based assays in both patients indi-
cated that clonal expansions are common in the blood of
rheumatoid arthritis patients. This type of result was
obtained with all individuals tested. It was most convinc-
ingly demonstrated by the results in Figure 3 obtained
from B cells expressing genes of the VH1 and VH3 fami-
lies. Because these VH families contain the largest
numbers of VH genes, they would be more likely to display
a polyclonal pattern.
An even more striking level of B-cell clonal dominance and
expansion was seen when the genomic DNA-based assay
was used to analyze B cells from the synovial fluid or syn-
ovial tissue (Figs 2 and 3). In these analyses, virtually all VH
families demonstrated extensive B-cell oligoclonality. It
should be pointed out that when an individual HCDR3
length comprises more than 50% of the radioactive
counts of a VH–CH ladder, clonality, based on DNA
sequencing, is very likely; when an individual length com-
prises more than 70% of the radioactivity, clonality is virtu-
ally assured (data not shown).
Collectively, these data indicate that the B-cell repertoire
of rheumatoid arthritis patients is skewed away from the
typical, apparently random representation of normal indi-
viduals. The reason for this discrepancy is not clear,
although one possibility is that restricted antigenic expo-
sure alters the composition of the repertoire in favor of B
cells reactive with the putative antigen(s). If this is so, the
progressive narrowing of the repertoire from the blood to
the synovial tissue is consistent with the ideas that the
antigenic exposures are originating at these sites and that
the synovial compartment is supporting clonal amplifica-
tion. Because these are true clonal expansions (ie
increased numbers of B cells per specific clone), it is likely
that the antigenic exposures are chronic and therefore are
increasing the numbers of memory B cells reactive with
these determinants.
In order to confirm that these clonally expanded B cells
were receiving ongoing antigenic stimulation and not
limited solely to the memory compartment, we employed
the cDNA-based assay to distinguish clonal expansions of
activated B cells from resting (memory) cells. As illustrated
in Figure 2, activated B-cell clones (identified by the letter
‘A’ in Fig. 2) expressing each of the immunoglobulin heavy-
chain isotypes were easily identified in all the VH families
studied. In some instances, these activated clones were
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Figure 2
Analyses of paired samples of blood (B) and
synovial fluid (SF) B cells from the same
rheumatoid arthritis patient. Results using both
the genomic DNA-based assay and the
complementary (c)DNA-based assay for the three
major immunoglobulin isotypes (M, G, and A) are
shown. Note that certain clones, as represented
by individual HCDR3 lengths, are restricted to the
blood (c), others to the joint (x), and others are
common to both compartments (r). E, expanded
clone; A, activated clone; E+A, same clone that is
both expanded and activated.
also expanded numerically (as defined by the genomic
DNA-based assays, and identified by the letter ‘E’ in
Fig. 2). In other cases, these activated clones did not
appear to be numerically expanded. Similar examples can
be found in Figures 3 and 4, but they are not identified by
letters in order to simplify the Figures. 
Thus, it appears that many discrete B-cell clones exist in
the synovial compartment of rheumatoid arthritis patients,
and that these are increased in number, consistent with a
response to a restricted antigenic challenge(s). Further-
more, these B-cell clones appear to be of both the resting
(memory) and the activated types, suggesting that these
antigenic challenges are chronic and ongoing. Thus, these
data support and extend previous findings [18–22] by
indicating that specific B-cell clonal amplifications can
occur both in previously stimulated B cells and in currently
activated B cells. The presence of activated B cells that
are not increased in number is consistent either with
recent in situ synovium-specific stimulation of these B-cell
clones, or with the influx of activated B cells that were
stimulated by antigens outside of and not necessarily rele-
vant to the synovial compartment.
B-cell clonal expansions in the blood and synovial
compartments can be restricted to one or another
compartment, or be common to the two
Because the preceding data indicated that the B-cell
repertoire of rheumatoid arthritis patients contains
expanded clones of B cells that can be resting or acti-
vated, we investigated whether the same clones could be
identified in both the blood and synovial compartments.
Figures 2 and 3 illustrate data that suggest that there are
expanded clones that are blood restricted, joint restricted,
or are common to both compartments. Examples of blood-
restricted clones are highlighted on Figures 2 and 3 with
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Figure 3
Analyses of paired samples of blood (B) and
synovial tissue (ST) B cells from the same
rheumatoid arthritis patient. Results using both
the genomic DNA-based assay and the
complementary (c)DNA-based assay for the three
major immunoglobulin isotypes (M, G, and A) are
shown. Certain clones are restricted to the blood
(c), others to the joint (x), and others are
common to both compartments (r).
the c symbol, those that are joint-restricted with the x
symbol, and those that are common to the two compart-
ments with the r symbol. These findings suggest that
there may be a degree of cellular trafficking between the
blood and the synovial tissues.
In order to address this issue, we studied the B cells of
the blood and two synovial sites (right and left hip) that
were obtained from the same patient within 3 h of each
other (Fig. 4). In this patient, the DNA-based assay pro-
vided examples of clonal expansions that were present in
only one joint (eg the VH3–JH and VH5–JH combinations in
Figure 4), and the companion cDNA-based assays indi-
cated that in some instances these expansions were either
activated or resting. In only rare instances, however, did
the data suggest that a similar clone was present in two
different synovial tissues. DNA sequence analyses con-
firmed the rarity of this event (data not shown). Thus it
appears that in most instances the clonal amplifications
occur in situ and are not the result of trafficking from one
anatomic site to another. If so, this would suggest that the
antigenic challenges driving these clonal expansions may
not be common to all synovial tissues, but may be gener-
ated independently at each site, possibly by ongoing
tissue breakdown.
Clonal persistence in the synovial fluid compartment
If the clonal expansions identified in the joints of rheuma-
toid arthritis patients are due to an ongoing response to
antigen, then one would predict that at least some of the
clones would persist over time. To test this, we studied
the synovial fluid B cells from the same joints of three
patients on two occasions spanning several months. Most
of the clonal expansions detected on the initial samples
were not present in the subsequent samples. In a few
instances, however, B-cell clonal persistence was found.
Figure 5 illustrates the best example of this phenomenon
in a patient who was studied over a 4-month interval. The
DNA-based assay using VH4 family-specific primers indi-
cated the presence of two similar clones on days 0 and
120, whereas the other VH4-expressing clones detected
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Figure 4
Analyses of B cells from paired samples of blood
(B) and synovial tissue from both the right (R) and
left (L) hips of the same rheumatoid arthritis
patient. Results using both the genomic DNA-
based assay and the complementary (c)DNA-
based assay for the three major immunoglobulin
isotypes (M, G, and A) are shown. R, clones that
are restricted to the right hip joint; L, clones that
are restricted to the left hip joint; R+L, clones that
are common to both the right and left hip joints.
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at the first analysis were no longer present at the time of
the second analysis. DNA sequence analyses of one of
these two clones confirmed their identity, because each
displayed the same rearranged VHDJH gene with identical
VH mutations and identical HCDR3 sequences (data not
shown). Therefore, certain clones can persist locally over
time, suggesting that a common and persistent antigenic
stimulation was operable in the joint of this rheumatoid
arthritis patient.
The lack of persistence of the other B-cell clones sug-
gests two possibilities. First, the initial set of B-cell clones
might have been replaced by others that recognized and
responded to different antigenic epitopes on the same
original immunogenic protein. This type of clonal evolution
to the recognition of different epitopes on the same
immunogenic moiety is common in experimental situations
in which repetitive immunizations with a defined antigen
are delivered [29–31]. The other possibility is that the B
cells that disappeared over time were not reactive with
tissue antigens. These could have been stimulated by irrel-
evant antigens in the periphery and therefore, after enter-
ing the synovial compartment, could not be restimulated
and hence could not enter the memory pool and take up
residence in the synovial tissue.
Conclusion
The present data indicate that clonal expansion is a
common occurrence in the B-cell repertoire of rheumatoid
arthritis patients. These expansions involve both resting
memory B cells and activated B cells, some of which are
derived from the memory B-cell compartment. Because the
extent of these clonal expansions increases from the blood
to the synovial compartment, this progressive narrowing in
diversity implies that antigens located in the synovia are
responsible for these antigen-receptor biases. In support of
this hypothesis are the observations that some of these
clonal expansions are joint specific. Because identical
clones are rarely found in two different joints, however,
these immune reactions are probably unique to each indi-
vidual joint. Furthermore, because it is unlikely that each
joint would harbor a different foreign antigen, these B cells
are most likely reacting with autoantigens generated
locally, possibly by local tissue breakdown. 
Recent studies [20,32] have demonstrated that the syn-
ovial tissue of rheumatoid arthritis patients can develop
lymphoid aggregates that have the cellular components of
an ectopic germinal center and that can sustain B-cell
clonal expansion and diversification. It is likely that the B
cells that mature in these ‘pseudogerminal centers’ and
those that we have identified in the present studies are
responding to specific (auto)antigens. Therefore, the iden-
tification of the antigenic reactivities of these B cells, and
in particular those B cells within the memory compartment
that have presumably traversed the pseudogerminal
centers and undergone (auto)antigen and T cell selection
and rescue, may provide important clues to the role of B
lymphocytes and their immunoglobulin molecules in the
immunopathogenesis of rheumatoid arthritis.
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